Encouraging Immune Response Seen in ''Prime/Boost'' Phase I HIV Vaccine Study
7th Sep 2005, 17:51 GMT
GenVec announced that preliminary safety and immune response data in a sample size of 8 healthy volunteers enrolled in one of several ongoing Phase I clinical trials involving an HIV vaccine candidate developed by GenVec and the Vaccine Research Center of the Nat'l Institute of Allergy and Infectious Diseases, NIH, showed that the vaccine regimen combining DNA priming and adenovector boosting was well tolerated and produced a vigorous cellular and antibody immune response.
Latest news from Financial News News from myHealthcareNews.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris